Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07418593 · ClinicalTrials.gov registry record · Phase 4
THE Malabsorption Blood Test Trial Will Help Determine THE Benefits OF Pancreatic Enzyme Replacement Therapy IN Patients With Mild TO Moderate Exocrine Pancreatic Insufficiency.
A Phase 4 study of Chronic Pancreatitis and Exocrine Pancreatic Insufficiency, sponsored by Anna Evans Phillips.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT07418593 is a Phase 4 study of Chronic Pancreatitis and Exocrine Pancreatic Insufficiency that is actively recruiting participants, run by Anna Evans Phillips. The registered enrollment target is 80 participants, below the 687-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07418593, a Phase 4 study of Chronic Pancreatitis and Exocrine Pancreatic Insufficiency, is actively recruiting participants, sponsored by Anna Evans Phillips.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
This project uses the Malabsorption Blood Test (MBT) to identify patients with recurrent acute or chronic pancreatitis who have mild to moderate exocrine pancreatic insufficiency. A subgroup of patients who have response to pancreatic enzyme replacement therapy will enter a randomized, placebo-controlled pilot clinical trial for 8 weeks to identify improvements in quality of life (QOL).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pancreatic Enzyme Replacement Therapy
- DIAGNOSTIC_TEST MBT1
- DIAGNOSTIC_TEST MBT 2
Study Locations (2)
Maryland
- Johns Hopkins Medicine - Baltimore
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07418593
The ClinicalTrials.gov registry entry for NCT07418593 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 687-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (88% lower). The listed sponsor is Anna Evans Phillips, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Pancreatitis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07418593 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07418593 about?
NCT07418593 is a clinical study titled "THE Malabsorption Blood Test Trial Will Help Determine THE Benefits OF Pancreatic Enzyme Replacement Therapy IN Patients With Mild TO Moderate Exocrine Pancreatic Insufficiency.". This project uses the Malabsorption Blood Test (MBT) to identify patients with recurrent acute or chronic pancreatitis who have mild to moderate exocrine pancreatic insufficiency. A subgroup of patients who have response to pancreatic enzyme replacement therapy will enter a randomized, placebo-contr...
What is the current status of trial NCT07418593?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2026-03. Estimated completion is 2028-09.
What conditions does trial NCT07418593 study?
This clinical trial studies the following conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency, Recurrent Acute Pancreatitis.
What interventions are being tested in trial NCT07418593?
The interventions under investigation include: Placebo (DRUG), Pancreatic Enzyme Replacement Therapy (DRUG), MBT1 (DIAGNOSTIC_TEST), MBT 2 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07418593?
This trial is sponsored by Anna Evans Phillips, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07418593 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Study of Celiac Block Injection: 1 vs. 2
COMPLETED · Phase 4
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
-
Analysis of Graft Function Following Autologous Islet Transplantation
RECRUITING
-
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
RECRUITING · Early Phase 1
-
Scrambler Therapy in Chronic Pancreatitis
RECRUITING · NA
-
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.